Annual FCF
-$5.01 M
+$5.90 M+54.06%
December 31, 2023
Summary
- As of February 10, 2025, ABIO annual free cash flow is -$5.01 million, with the most recent change of +$5.90 million (+54.06%) on December 31, 2023.
- During the last 3 years, ABIO annual FCF has risen by +$2.73 million (+35.25%).
Performance
ABIO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly FCF
-$2.63 M
-$1.11 M-72.38%
June 30, 2024
Summary
- As of February 10, 2025, ABIO quarterly free cash flow is -$2.63 million, with the most recent change of -$1.11 million (-72.38%) on June 30, 2024.
- Over the past year, ABIO quarterly FCF has dropped by -$1.58 million (-149.43%).
Performance
ABIO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM FCF
-$6.89 M
-$1.94 M-39.22%
June 30, 2024
Summary
- As of February 10, 2025, ABIO TTM free cash flow is -$6.89 million, with the most recent change of -$1.94 million (-39.22%) on June 30, 2024.
- Over the past year, ABIO TTM FCF has dropped by -$1.87 million (-37.36%).
Performance
ABIO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ABIO Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +54.1% | -149.4% | -37.4% |
| 3 y3 years | +35.3% | +46.1% | +59.1% |
| 5 y5 years | +39.2% | +46.1% | +59.1% |
ABIO Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +275.0% | +279.5% | +88.1% | +39.2% | +173.1% |
| 5 y | 5-year | +4.3% | +275.0% | +279.5% | +98.6% | +44.0% | +173.1% |
| alltime | all time | +23.0% | +1128.7% | -114.1% | +1020.1% | +262.5% | +981.5% |
ARCA Biopharma Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2024 | - | -$2.63 M(+72.4%) | -$6.89 M(+39.2%) |
| Mar 2024 | - | -$1.53 M(+44.7%) | -$4.95 M(-1.3%) |
| Dec 2023 | -$5.01 M(-54.1%) | -$1.06 M(-36.7%) | -$5.01 M(-8.0%) |
| Sep 2023 | - | -$1.67 M(+140.5%) | -$5.45 M(-13.2%) |
| Jun 2023 | - | -$694.00 K(-56.5%) | -$6.28 M(-23.5%) |
| Mar 2023 | - | -$1.59 M(+6.8%) | -$8.21 M(-24.8%) |
| Dec 2022 | -$10.91 M(-42.0%) | -$1.49 M(-40.2%) | -$10.91 M(-24.1%) |
| Sep 2022 | - | -$2.50 M(-4.7%) | -$14.37 M(-14.2%) |
| Jun 2022 | - | -$2.62 M(-39.0%) | -$16.76 M(-6.2%) |
| Mar 2022 | - | -$4.30 M(-13.2%) | -$17.87 M(-5.0%) |
| Dec 2021 | -$18.80 M(+142.8%) | -$4.95 M(+1.4%) | -$18.80 M(+11.5%) |
| Sep 2021 | - | -$4.88 M(+30.7%) | -$16.86 M(+20.6%) |
| Jun 2021 | - | -$3.74 M(-28.6%) | -$13.98 M(+23.8%) |
| Mar 2021 | - | -$5.23 M(+73.9%) | -$11.29 M(+45.7%) |
| Dec 2020 | -$7.74 M(+61.2%) | -$3.01 M(+50.2%) | -$7.74 M(+31.3%) |
| Sep 2020 | - | -$2.00 M(+91.6%) | -$5.90 M(+23.3%) |
| Jun 2020 | - | -$1.04 M(-38.1%) | -$4.78 M(-2.9%) |
| Mar 2020 | - | -$1.69 M(+45.6%) | -$4.93 M(+2.6%) |
| Dec 2019 | -$4.80 M(-41.7%) | -$1.16 M(+30.5%) | -$4.80 M(-3.7%) |
| Sep 2019 | - | -$889.00 K(-25.3%) | -$4.99 M(-12.2%) |
| Jun 2019 | - | -$1.19 M(-24.0%) | -$5.68 M(-15.8%) |
| Mar 2019 | - | -$1.57 M(+16.6%) | -$6.74 M(-18.3%) |
| Dec 2018 | -$8.25 M(-52.8%) | -$1.34 M(-14.9%) | -$8.25 M(-25.7%) |
| Sep 2018 | - | -$1.58 M(-29.9%) | -$11.10 M(-17.7%) |
| Jun 2018 | - | -$2.25 M(-26.6%) | -$13.50 M(-16.7%) |
| Mar 2018 | - | -$3.07 M(-26.8%) | -$16.20 M(-7.3%) |
| Dec 2017 | -$17.48 M(+16.5%) | -$4.20 M(+5.6%) | -$17.48 M(+2.0%) |
| Sep 2017 | - | -$3.97 M(-19.9%) | -$17.12 M(+1.4%) |
| Jun 2017 | - | -$4.96 M(+14.2%) | -$16.89 M(+9.3%) |
| Mar 2017 | - | -$4.34 M(+12.9%) | -$15.46 M(+3.1%) |
| Dec 2016 | -$15.00 M(+42.2%) | -$3.85 M(+2.8%) | -$15.00 M(+8.9%) |
| Sep 2016 | - | -$3.74 M(+6.1%) | -$13.78 M(+10.8%) |
| Jun 2016 | - | -$3.53 M(-9.2%) | -$12.44 M(+9.9%) |
| Mar 2016 | - | -$3.88 M(+48.1%) | -$11.31 M(+7.3%) |
| Dec 2015 | -$10.54 M(+11.9%) | -$2.62 M(+9.1%) | -$10.54 M(+7.4%) |
| Sep 2015 | - | -$2.40 M(0.0%) | -$9.82 M(+3.4%) |
| Jun 2015 | - | -$2.40 M(-22.8%) | -$9.49 M(+7.2%) |
| Mar 2015 | - | -$3.12 M(+64.6%) | -$8.85 M(-6.1%) |
| Dec 2014 | -$9.43 M(+77.2%) | -$1.89 M(-8.9%) | -$9.43 M(+0.2%) |
| Sep 2014 | - | -$2.08 M(+17.5%) | -$9.41 M(+4.3%) |
| Jun 2014 | - | -$1.77 M(-52.0%) | -$9.02 M(+9.5%) |
| Mar 2014 | - | -$3.69 M(+96.5%) | -$8.23 M(+54.8%) |
| Dec 2013 | -$5.32 M(+30.5%) | -$1.88 M(+11.2%) | -$5.32 M(+29.3%) |
| Sep 2013 | - | -$1.69 M(+71.4%) | -$4.11 M(+28.5%) |
| Jun 2013 | - | -$984.00 K(+27.3%) | -$3.20 M(+0.2%) |
| Mar 2013 | - | -$773.00 K(+15.5%) | -$3.19 M(-21.7%) |
| Dec 2012 | -$4.08 M(-41.6%) | -$669.00 K(-13.7%) | -$4.08 M(-12.5%) |
| Sep 2012 | - | -$775.00 K(-20.8%) | -$4.66 M(-16.2%) |
| Jun 2012 | - | -$978.00 K(-40.9%) | -$5.56 M(-16.9%) |
| Mar 2012 | - | -$1.66 M(+32.1%) | -$6.69 M(-4.1%) |
| Dec 2011 | -$6.98 M(-16.2%) | -$1.25 M(-25.2%) | -$6.98 M(+1.6%) |
| Sep 2011 | - | -$1.68 M(-20.5%) | -$6.87 M(-4.7%) |
| Jun 2011 | - | -$2.11 M(+8.6%) | -$7.20 M(+1.0%) |
| Mar 2011 | - | -$1.94 M(+69.7%) | -$7.13 M(-14.3%) |
| Dec 2010 | -$8.33 M | -$1.14 M(-43.1%) | -$8.33 M(-17.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2010 | - | -$2.01 M(-1.2%) | -$10.09 M(-45.7%) |
| Jun 2010 | - | -$2.04 M(-35.1%) | -$18.59 M(-32.2%) |
| Mar 2010 | - | -$3.14 M(+7.8%) | -$27.43 M(-34.6%) |
| Dec 2009 | -$41.91 M(+112.3%) | -$2.91 M(-72.3%) | -$41.91 M(+106.4%) |
| Sep 2009 | - | -$10.50 M(-3.5%) | -$20.30 M(-48.3%) |
| Jun 2009 | - | -$10.88 M(-38.2%) | -$39.30 M(+88.6%) |
| Mar 2009 | - | -$17.62 M(-194.2%) | -$20.84 M(+5.6%) |
| Dec 2008 | -$19.75 M(-57.4%) | $18.70 M(-163.4%) | -$19.75 M(-62.1%) |
| Sep 2008 | - | -$29.50 M(-489.2%) | -$52.12 M(+115.6%) |
| Jun 2008 | - | $7.58 M(-145.9%) | -$24.18 M(-46.8%) |
| Mar 2008 | - | -$16.52 M(+20.8%) | -$45.47 M(-1.9%) |
| Dec 2007 | -$46.34 M(+17.3%) | -$13.68 M(+775.0%) | -$46.34 M(-3.8%) |
| Sep 2007 | - | -$1.56 M(-88.6%) | -$48.18 M(-32.6%) |
| Jun 2007 | - | -$13.71 M(-21.2%) | -$71.46 M(-4.1%) |
| Mar 2007 | - | -$17.39 M(+12.1%) | -$74.48 M(+88.6%) |
| Dec 2006 | -$39.50 M(-35.9%) | -$15.52 M(-37.6%) | -$39.50 M(-7.5%) |
| Sep 2006 | - | -$24.85 M(+48.6%) | -$42.70 M(+24.1%) |
| Jun 2006 | - | -$16.73 M(-195.1%) | -$34.40 M(+8.8%) |
| Mar 2006 | - | $17.59 M(-194.0%) | -$31.60 M(-48.7%) |
| Dec 2005 | -$61.60 M(+21.3%) | -$18.71 M(+13.1%) | -$61.60 M(-0.4%) |
| Sep 2005 | - | -$16.54 M(+18.7%) | -$61.82 M(+11.6%) |
| Jun 2005 | - | -$13.93 M(+12.2%) | -$55.42 M(+2.3%) |
| Mar 2005 | - | -$12.41 M(-34.4%) | -$54.16 M(+6.7%) |
| Dec 2004 | -$50.78 M(+11.9%) | -$18.93 M(+86.7%) | -$50.78 M(+17.0%) |
| Sep 2004 | - | -$10.14 M(-20.0%) | -$43.41 M(+2.1%) |
| Jun 2004 | - | -$12.68 M(+40.4%) | -$42.51 M(-2.5%) |
| Mar 2004 | - | -$9.03 M(-21.9%) | -$43.62 M(-3.9%) |
| Dec 2003 | -$45.39 M(+37.7%) | -$11.56 M(+25.1%) | -$45.39 M(+9.6%) |
| Sep 2003 | - | -$9.24 M(-33.0%) | -$41.42 M(+4.5%) |
| Jun 2003 | - | -$13.79 M(+27.7%) | -$39.65 M(+15.6%) |
| Mar 2003 | - | -$10.79 M(+42.1%) | -$34.30 M(+4.0%) |
| Dec 2002 | -$32.97 M(-4.9%) | -$7.60 M(+1.7%) | -$32.97 M(-1.8%) |
| Sep 2002 | - | -$7.47 M(-11.5%) | -$33.58 M(-9.0%) |
| Jun 2002 | - | -$8.44 M(-10.8%) | -$36.90 M(+0.9%) |
| Mar 2002 | - | -$9.47 M(+15.4%) | -$36.56 M(+5.5%) |
| Dec 2001 | -$34.66 M(+18.5%) | -$8.20 M(-24.0%) | -$34.66 M(-5.5%) |
| Sep 2001 | - | -$10.79 M(+33.1%) | -$36.68 M(+4.9%) |
| Jun 2001 | - | -$8.11 M(+7.1%) | -$34.96 M(-3.2%) |
| Mar 2001 | - | -$7.57 M(-26.0%) | -$36.11 M(+23.4%) |
| Dec 2000 | -$29.26 M(+68.1%) | -$10.22 M(+12.8%) | -$29.26 M(+57.0%) |
| Sep 2000 | - | -$9.06 M(-2.1%) | -$18.63 M(+22.8%) |
| Jun 2000 | - | -$9.26 M(+1204.2%) | -$15.17 M(+51.5%) |
| Mar 2000 | - | -$710.00 K(-277.5%) | -$10.01 M(-42.5%) |
| Dec 1999 | -$17.40 M(+6.7%) | $400.00 K(-107.1%) | -$17.40 M(-7.4%) |
| Sep 1999 | - | -$5.60 M(+36.6%) | -$18.80 M(-3.6%) |
| Jun 1999 | - | -$4.10 M(-49.4%) | -$19.50 M(-14.5%) |
| Mar 1999 | - | -$8.10 M(+710.0%) | -$22.80 M(+39.9%) |
| Dec 1998 | -$16.30 M(+45.5%) | -$1.00 M(-84.1%) | -$16.30 M(-20.9%) |
| Sep 1998 | - | -$6.30 M(-14.9%) | -$20.60 M(+19.1%) |
| Jun 1998 | - | -$7.40 M(+362.5%) | -$17.30 M(+58.7%) |
| Mar 1998 | - | -$1.60 M(-69.8%) | -$10.90 M(-2.7%) |
| Dec 1997 | -$11.20 M(+115.4%) | -$5.30 M(+76.7%) | -$11.20 M(+89.8%) |
| Sep 1997 | - | -$3.00 M(+200.0%) | -$5.90 M(+103.4%) |
| Jun 1997 | - | -$1.00 M(-47.4%) | -$2.90 M(+52.6%) |
| Mar 1997 | - | -$1.90 M | -$1.90 M |
| Dec 1996 | -$5.20 M | - | - |
FAQ
- What is ARCA biopharma annual free cash flow?
- What is the all time high annual FCF for ARCA biopharma?
- What is ARCA biopharma annual FCF year-on-year change?
- What is ARCA biopharma quarterly free cash flow?
- What is the all time high quarterly FCF for ARCA biopharma?
- What is ARCA biopharma quarterly FCF year-on-year change?
- What is ARCA biopharma TTM free cash flow?
- What is the all time high TTM FCF for ARCA biopharma?
- What is ARCA biopharma TTM FCF year-on-year change?
What is ARCA biopharma annual free cash flow?
The current annual FCF of ABIO is -$5.01 M
What is the all time high annual FCF for ARCA biopharma?
ARCA biopharma all-time high annual free cash flow is -$4.08 M
What is ARCA biopharma annual FCF year-on-year change?
Over the past year, ABIO annual free cash flow has changed by +$5.90 M (+54.06%)
What is ARCA biopharma quarterly free cash flow?
The current quarterly FCF of ABIO is -$2.63 M
What is the all time high quarterly FCF for ARCA biopharma?
ARCA biopharma all-time high quarterly free cash flow is $18.70 M
What is ARCA biopharma quarterly FCF year-on-year change?
Over the past year, ABIO quarterly free cash flow has changed by -$1.58 M (-149.43%)
What is ARCA biopharma TTM free cash flow?
The current TTM FCF of ABIO is -$6.89 M
What is the all time high TTM FCF for ARCA biopharma?
ARCA biopharma all-time high TTM free cash flow is -$1.90 M
What is ARCA biopharma TTM FCF year-on-year change?
Over the past year, ABIO TTM free cash flow has changed by -$1.87 M (-37.36%)